Cardiologycardiovascular riskGLP-1 receptor agonists
Synergistic Protection: Combining GLP-1 Receptor Agonists with Lifestyle Habits Slashes Cardiovascular Risk in Type 2 Diabetes
By MedXY|Mar 7, 2026
A massive cohort study of nearly 100,000 veterans reveals that while GLP-1 receptor agonists significantly reduce MACE, the combination with a healthy lifestyle offers a 43% lower risk, emphasizing the need for integrated cardiometabolic ca
